A Review of Existing Therapies for Actinic Keratosis: Current Status and Future Directions

被引:27
|
作者
Del Regno, Laura [1 ]
Catapano, Silvia [2 ]
Di Stefani, Alessandro [1 ,2 ]
Cappilli, Simone [2 ]
Peris, Ketty [1 ,2 ]
机构
[1] Fdn Policlin Univ A Gemelli IRCCS, Inst Dermatol, Dipartimento Sci Med & Chirurg, Dermatol, Largo A Gemelli 8, I-00168 Rome, Italy
[2] Univ Cattolica Sacro Cuore, Dipartimento Univ Med & Chirurg Traslaz, Dermatol, Rome, Italy
关键词
SQUAMOUS-CELL CARCINOMA; 35-PERCENT TRICHLOROACETIC-ACID; DAYLIGHT PHOTODYNAMIC THERAPY; LONG-TERM EFFICACY; DOUBLE-BLIND; METHYL AMINOLEVULINATE; SALICYLIC-ACID; IMIQUIMOD; 2.5-PERCENT; TOPICAL TREATMENTS; RANDOMIZED-TRIAL;
D O I
10.1007/s40257-022-00674-3
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Actinic keratosis (AK) is a chronic skin disease in which clinical and subclinical cutaneous lesions coexist on sun-exposed areas such as the head and neck region and the extremities. The high prevalence of AK means the disease burden is substantial, especially in middle-aged and elderly populations. Evidence indicates that AK may progress into invasive cutaneous squamous cell carcinoma, so the European guidelines recommend treatment of any AK regardless of clinical severity. Given the aging population and therefore the increasing incidence of AK and cutaneous field carcinogenesis, further updates on the long-term efficacy of current therapies and new investigational agents are critical to guide treatment choice. Patients often have difficulty adequately applying topical treatments and coping with adverse local skin reactions, leading to less than optimum treatment adherence. The development of associated local skin symptoms and cosmetic outcomes for the area of interest are also relevant to the choice of an appropriate therapeutic strategy. Treatment is always individually tailored according to the characteristics of both patients and lesions. This review focuses on the therapeutic approaches to AK and illustrates the currently available home-based and physician-managed treatments.
引用
收藏
页码:339 / 352
页数:14
相关论文
共 50 条
  • [41] Actinic keratosis - review for clinical practice
    de Oliveira, Erika C. V.
    da Motta, Valeria R. V.
    Pantoja, Paola C.
    Ilha, Carolina S. de O.
    Magalhaes, Renata F.
    Galadari, Hassan
    Leonardi, Gislaine R.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2019, 58 (04) : 400 - 407
  • [42] Bevacizumab - current status and future directions
    Midgley, R
    Kerr, D
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 999 - 1004
  • [43] Current status and future directions of The Annals
    Nahata, MC
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (02) : 321 - 322
  • [44] Colletotrichum - current status and future directions
    Cannon, P. F.
    Damm, U.
    Johnston, P. R.
    Weir, B. S.
    STUDIES IN MYCOLOGY, 2012, (73) : 181 - 213
  • [45] Vasculitis: Current status and future directions
    Youinou, Pierre
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2008, 35 (1-2) : 1 - 4
  • [46] Schizotaxia: Current status and future directions
    Ming T. Tsuang
    William S. Stone
    Franziska Gamma
    Stephen V. Faraone
    Current Psychiatry Reports, 2003, 5 (2) : 128 - 134
  • [47] Vasculitis: Current Status and Future Directions
    Pierre Youinou
    Clinical Reviews in Allergy & Immunology, 2008, 35 : 1 - 4
  • [48] Current status and future directions of geoportals
    Jiang, Hao
    van Genderen, John
    Mazzetti, Paolo
    Koo, Hyeongmo
    Chen, Min
    INTERNATIONAL JOURNAL OF DIGITAL EARTH, 2020, 13 (10) : 1093 - 1114
  • [49] Biosimilars: current status and future directions
    Roger, Simon D.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (07) : 1011 - 1018
  • [50] Teledermatology: Current status and future directions
    Whited J.D.
    American Journal of Clinical Dermatology, 2001, 2 (2) : 59 - 64